A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Completed · Phase 2
Conditions studied: Locally Recurrent, Metastatic Breast Cancer ( HER2 Negative)
In brief
The purpose of this study is to assess the efficacy and safety of single-agent eribulin mesylate for first-line treatment of subjects with locally recurrent or metastatic breast cancer.
Key facts
- Study ID
- NCT01268150
- Run by
- Eisai Inc.
- People needed
- 56
- Starts
- 2011-02-01
- Expected to finish
- 2013-08-01
- Last updated by the study team
- 2023-06-22
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- University of Miami — Miami, Florida, United States
- Augusta Oncology Associates — Augusta, Georgia, United States
- Central Georgia Cancer Care — Macon, Georgia, United States
- Northwest Georgia Oncology Centers, P.C. — Marietta, Georgia, United States
- Central Indiana Cancer Centers — Indianapolis, Indiana, United States
- Missouri Cancer Associates — Columbia, Missouri, United States
- Hematology Oncology Centers of Northern Rockies — Billings, Montana, United States
- New York Oncology Hematology, P.C. — Albany, New York, United States
- Weill Cornell Medical Center — New York, New York, United States
- Northwest Cancer Specialists, P.C. — Portland, Oregon, United States
- The West Clinic — Memphis, Tennessee, United States
- Texas Oncology- Bedford — Bedford, Texas, United States
- Texas Oncology - Medical City Dallas — Dallas, Texas, United States
- Texas Oncology-Dallas Presbyterian Hospital — Dallas, Texas, United States
- Cancer Care Centers of South Texas — San Antonio, Texas, United States
- Texas Oncology- Tyler — Tyler, Texas, United States
- Columbia Basin Hematology and Oncology — Kennewick, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.